Versican Plus L4
Active substance
ATC code
Species
Dogs.
Indications
Active immunisation of dogs from 6 weeks of age:
|
− |
to prevent clinical signs, infection and urinary excretion caused by L. interrogans serogroup Australis serovar Bratislava, |
|
− |
to prevent clinical signs and urinary excretion and reduce infection caused by L. interrogans serogroup Canicola serovar Canicola and L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae and |
|
− |
to prevent clinical signs and reduce infection and urinary excretion caused by L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa. |
Onset of immunity:
4 weeks after completion of the primary course.
Duration of immunity:
At least one year following the primary vaccination course for all components of Versican Plus L4.
Dose to be administered and administration route
Subcutaneous use.
Dosage and route of administration:
Shake well and administer immediately the entire contents (1 ml) of the product.
Primary vaccination scheme:
Two doses of Versican Plus L4 3-4 weeks apart from 6 weeks of age.
Re-vaccination scheme:
A single dose of Versican Plus L4 to be given annually.
Adverse reactions
Dogs:
|
Common (1 to 10 animals / 100 animals treated): |
injection site swelling1 |
|
Rare (1 to 10 animals / 10,000 animals treated): |
hypersensitivity reaction2 (anaphylaxis, angioedema, circulatory shock, collapse, diarrhoea, dyspnoea, vomiting) anorexia, decreased activity |
|
Very rare (<1 animal / 10,000 animals treated, including isolated reports): |
hyperthermia, lethargy, malaise immune mediated haemolytic anaemia, immune mediated haemolytic thrombocytopenia, immune mediated polyarthritis |
1 A transient swelling (up to 5 cm) which can be painful, warm or reddened. Any such swelling will either have spontaneously resolved or be greatly diminished by 14 days after vaccination.
2 If a hypersensitivity reaction occurs, appropriate treatment should be administered without delay. Such reactions may evolve to a more severe condition which may be life-threatening.
Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See section “Contact details” of the package leaflet for respective contact details.
TRUSTED SOURCE
